Today: Today, Sinovac Biotech Ltd. (SVA) Set to Announce Quarterly Earnings on Monday

Today, Sinovac Biotech Ltd. (SVA) Set to Announce Quarterly Earnings on Monday

Sinovac Biotech Ltd. (NASDAQ:SVA) is scheduled to be issuing its Q316 quarterly earnings data on Monday, November 28th.

Sinovac Biotech (NASDAQ:SVA) last issued its quarterly earnings results on Tuesday, August 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The business had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $18.49 billion. Sinovac Biotech had a negative return on equity of 10.26% and a negative net margin of 17.94%. During the same period in the prior year, the business earned $0.02 earnings per share. On average, analysts expect Sinovac Biotech to post $-0.05 EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

Sinovac Biotech Ltd. (NASDAQ:SVA) opened at 6.16 on Friday. The company’s market capitalization is $350.72 million. Sinovac Biotech Ltd. has a 1-year low of $4.38 and a 1-year high of $7.16. The company has a 50 day moving average of $6.05 and a 200 day moving average of $5.95.

Institutional investors have recently bought and sold shares of the company. Credit Suisse AG raised its position in shares of Sinovac Biotech by 48.2% in the third quarter. Credit Suisse AG now owns 89,428 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 29,085 shares during the period. Panagora Asset Management Inc. raised its position in shares of Sinovac Biotech by 4.7% in the second quarter. Panagora Asset Management Inc. now owns 42,816 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 1,929 shares during the period. State Street Corp acquired a new position in shares of Sinovac Biotech during the second quarter valued at about $100,000. TFS Capital LLC raised its position in shares of Sinovac Biotech by 86.8% in the second quarter. TFS Capital LLC now owns 24,650 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 11,451 shares during the period. Finally, OMERS ADMINISTRATION Corp raised its position in shares of Sinovac Biotech by 5.6% in the second quarter. OMERS ADMINISTRATION Corp now owns 35,700 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 1,900 shares during the period. 19.07% of the stock is currently owned by institutional investors.

Separately, TheStreet lowered Sinovac Biotech from a “hold” rating to a “sell” rating in a research note on Wednesday, August 24th.

About Sinovac Biotech

Related posts

Leave a Comment